作者
Vincent P Groot, Stacy Mosier, Ammar A Javed, Jonathan A Teinor, Georgios Gemenetzis, Ding Ding, Lisa M Haley, Jun Yu, Richard A Burkhart, Alina Hasanain, Marija Debeljak, Hirohiko Kamiyama, Amol Narang, Daniel A Laheru, Lei Zheng, Ming-Tseh Lin, Christopher D Gocke, Elliot K Fishman, Ralph H Hruban, Michael G Goggins, I Quintus Molenaar, John L Cameron, Matthew J Weiss, Victor E Velculescu, Jin He, Christopher L Wolfgang, James R Eshleman
发表日期
2019/8/15
期刊
Clinical Cancer Research
卷号
25
期号
16
页码范围
4973-4984
出版商
American Association for Cancer Research
简介
Purpose
In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform analytical and clinical validation of a KRAS ctDNA assay in a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathology–certified clinical laboratory.
Experimental Design
Digital-droplet PCR was used to detect the major PDAC-associated somatic KRAS mutations (G12D, G12V, G12R, and Q61H) in liquid biopsies. For clinical validation, 290 preoperative and longitudinal postoperative plasma samples were collected from 59 patients with PDAC. The utility of ctDNA status to predict PDAC recurrence during follow-up was assessed.
Results
ctDNA was detected preoperatively in 29 (49%) patients and was an independent predictor of decreased …
学术搜索中的文章
VP Groot, S Mosier, AA Javed, JA Teinor… - Clinical Cancer Research, 2019